OCS News & Events

Stock futures are showing modest movement, reflecting a pause after recent record highs. Traders appear reluctant to push markets sharply higher without fresh near-term catalysts, especially as they look ahead to key economic data including employment reports later this week.Despite the restraint in equity moves, commodities and precious metals remain supportive for markets. Oil prices have resumed their climb and both gold and silver futures are extending gains amid ongoing geopolitical tension and macro uncertainty. Meanwhile, technology stocks are getting fresh attention around the CES 2026 trade show, with new AI chip announcements contributing to sector confidence, even as investors balance that optimism with caution.In pre-market trading, S&P 500 futures rose 0.01%, Nasdaq futures rose 0.16% and Dow futures fell 0.06%.Check out this morning's top movers from around Wall Street, compiled by The Fly.HIGHER -Aevaup 28% after announcing 4D LiDAR integration within NvidiaDrive HyperionOneStreamup 27% after BloombergHg is in advanced talks to acquire the companyOculisup 8% after Privosegtor was granted breakthrough therapy designation by the FDAZeta Globalup 8% after announcing a strategic collaboration with OpenAIMicrochipup 4% after raising its Q3 revenue guidanceVistraup 4% after agreeing to acquire Cogentrix Energy for $4BLOWER -Madrigal Pharmaceuticalsdown 2% after Wolfe Research downgraded the stock to Peer Perform and removed the firm's prior $579 price targetWeavedown 1% after Raymond James downgraded shares to Outperform from Strong Buy with a price target of $10, down from $12Lennardown 1% after UBS downgraded the stock to Neutral with a price target of $122, down from $137D.R. Hortondown 1% after Wells Fargo downgraded shares to Equal Weight with a price target of $155, down from $180

Oculis Holding announced that its neuroprotective candidate Privosegtor was granted breakthrough therapy designation by the U.S. Food and Drug Administration for treatment of optic neuritis. The FDA's Breakthrough Therapy Designation for Privosegtor is supported by visual-function results from the Phase 2 ACUITY trial in optic neuritis. In the trial, Privosegtor delivered substantial improvement in LCVA along with consistent anatomical and biological benefits compared with placebo, reinforcing its potential as a neuroprotective treatment across both neuro-ophthalmic and neurological diseases. In the ACUITY trial, Privosegtor produced substantial vision improvements on the 2.5% ETDRS Low Contrast Letter Acuity chart. Following a successful meeting with the FDA in 2025, Oculis launched the PIONEER program, which includes three pivotal trials to support registration plans for Privosegtor in ON and a second rare neuro-ophthalmic disease, NAION. The first trial in the program, PIONEER-1 in ON, was initiated in Q4 last year. This global study spans three continents. Sites activation is underway, and enrollment is expected to begin shortly. Shares of Oculis are up 9% in premarket trading.